Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum-Reference-Cited by-同舟云学术

Randomized Trial of Single Agent Paclitaxel Given Weekly Versus Every Three Weeks and with Peroral Versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum

Published:2002-01 Issue:5 Volume:41 Page:418-424
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Rosenberg Per,Andersson Ha˚kan,Boman Karin,Ridderheim Mona,Sorbe Bengt,Puistola Ulla,Parö Gunnar

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/028418602320404998

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study;Current Oncology;2024-08-15

2. Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study;Journal of Oncology Pharmacy Practice;2024-07-23

3. Is a low dose of dexamethasone sufficient to prevent paclitaxel-related hypersensitivity reactions? A retrospective study in patients with gynecologic malignancy;Expert Review of Clinical Pharmacology;2024-04-23

4. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2022-07-12

5. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review;Clinical Reviews in Allergy & Immunology;2022-03-08